Numi.To

NUMI.TO's capital structure is highly leveraged, with a debt-to-equity ratio of 2.8, indicating significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 1.14 and negative free cash flow of -14,064,240 CAD, which suggests limited ability to meet short-term obligations without external financing.

Profitability metrics are deeply negative, with a return on equity of -27.08% and a return on assets of -1.82%, both well below industry norms for biotechnology firms. The company reported a net loss of 19,642,840 CAD and an operating loss of 12,585,390 CAD, indicating a lack of operational efficiency and a failure to generate positive returns on invested capital.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the ability to offset losses in one area with gains in another.

Growth trajectory is negative, with a reported revenue of 4,168,450 CAD, which is below the analyst estimate of 23,180,500 CAD. The company is expected to continue experiencing declining revenues in the near term, with no clear path to profitability or positive cash flow generation.

Risk factors include a high debt load, negative cash flow, and a weak equity position. The company has a low dilution risk, but its liquidity risk is medium, and its credit risk is elevated due to the negative net cash position after subtracting total debt. The company has not disclosed any recent capital raising activities or dilution events, but its financial position suggests a potential need for further financing in the near term.

Recent events include the continued underperformance relative to analyst expectations, with actual revenue significantly below the estimated 23,180,500 CAD. No recent filings or transcripts have been disclosed that provide insight into strategic changes or operational improvements.